Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.54 |
| ▸ | BRAF | P15056 | 3/20 | 0.54 |
| ▸ | CDK8 | P49336 | 7/20 | 0.44 |
| ▸ | CCNC | P24863 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550169 | 0.91 | RAF1 (0.56) | RAF1BRAFCDK8CCNCKDR | |
| SCHEMBL3545192 | 0.89 | RAF1 (0.62) | RAF1BRAFCDK8KDRMAPT | |
| SCHEMBL3537679 | 0.88 | RAF1 (0.61) | RAF1BRAFCDK8KDRMAPT | |
| SCHEMBL3546626 | 0.87 | RAF1 (0.53) | RAF1BRAFCDK8CCNCKDR | |
| SCHEMBL6098859 | 0.84 | CDK8 (0.45) | RAF1BRAFCDK8CCNCKDR | |
| SCHEMBL6098842 | 0.84 | CDK8 (0.45) | RAF1BRAFCDK8CCNCKDR | |
| SCHEMBL3547729 | 0.84 | RAF1 (0.60) | RAF1BRAFCDK8KDRMAPT | |
| SCHEMBL3543186 | 0.81 | BRAF (0.71) | RAF1BRAFCDK8KDRMAPT | |
| SCHEMBL3547071 | 0.79 | RAF1 (0.68) | RAF1BRAFCDK8CCNCKDR | |
| SCHEMBL3550793 | 0.77 | RAF1 (0.58) | RAF1BRAFCDK8CCNCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | RAF1 693/4885BRAF 794/4885CDK8 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.